Empagliflozin Approval May Come This Year After Boehringer Resolves GMP Problems
This article was originally published in The Pink Sheet Daily
Executive Summary
BI/Lilly’s SGLT-2 inhibitor is to be manufactured in a facility that was subject to a May 2013 warning letter from FDA.